Research Grants

Funding scheme

Website & info

Details

Min data/ EOI/ etc.

External due date

*Dates of currently closed opportunities are indicative only and will be updated as they become available

The CURE Epilepsy Award (2 years / $250,000) reflects CURE Epilepsy’s continued focus on scientific advances that have the potential to truly transform the lives of those affected by epilepsy, with prevention and disease modification as critical goals. Key priority areas for the award include: 1) Basic mechanisms of epilepsy; 2) Acquired epilepsies; 3) Pediatric epilepsies; 4) SUDEP; 5) Treatment-resistant epilepsies; and 6) Sleep & epilepsy.

Please refer to the LOI guidelines for an overview of CURE Epilepsy’s priority areas, application instructions, and FAQs.

Lloyd J. Old

STAR Program

This long-term funding will not be tied to a specific research project, but rather will aim to provide a degree of flexibility and freedom for investigators to explore out-of-the-box and disruptive avenues of research. Candidates selected for this award are expected to be future “stars” in the field of cancer immunology: Scientists Taking Risks.

Guidelines & application form:

https://www.cancerresearch.org/scientists/fellowships-grants/lloyd-j-old-star-program/star-application-guidelines

Applicants must belong to one of the following categories as of July 1, 2020:

• Tenure-track assistant professor with a minimum of 3 years in this position (appointed on or before July 1, 2017)
• Tenure-track associate professor with a maximum of 3 years in this position (appointed on or after July 1, 2017)

Interested in applying? Email Uli and Brittany to let them know.

$1.25 million over 5 years

15 Jan 21

Mission:

• To make grants to fund relevant nutritional research.
• To support programs for the education and training of mothers during pregnancy and after the birth of their children, so that good nutritional habits can be formed at an early age.
• To assist in the training of persons to work as educators and demonstrators of good nutritional practices.
• To encourage the dissemination of information regarding healthful nutritional practices and habits.
• In limited situations to make grants to help solve immediate emergency hunger and malnutrition problems.

The connections between diet and health remain a basic and primary priority, and consideration has always been given to projects that benefit nutritional programs in the areas of education, training, and research. Low priority has traditionally been given to proposals that help solve immediate or emergency hunger and malnutrition problems. The foundation does not under any circumstances sponsor professional conferences, seminar tables, discussion panels, or similar events. The foundation welcomes proposals that develop and advance: (1) the inclusion of mandatory courses in nutrition in medical schools; (2) bringing the promise of nutrigenomics or nutritional genomics to realization; and (3) the promotion of environmentally sound, economically viable, socially responsive, and sustainable food and agricultural systems.

for information on how to apply see: https://allenfoundation.org/how-to-apply/

Interested in applying? Email Uli and Brittany to let them know.

MRFF

EPCDR Initiative 2020

Childhood Cancer Research Grant Opportunity

GO4456 GrantConnect: https://www.grants.gov.au/     

UQ documents can be found here.

the objective of this grant opportunity is to provide grants of financial assistance to support Australian medical research and medical innovation projects that improve our understanding of the aetiology, biology and progression of cancer in children and adolescents.
The grant opportunity will fund projects in two streams of research:

• Stream 1 – Cancer in children
      Research that investigates cancers that occur in children (age range 0-14 years)

• Stream 2 – Cancer in adolescents
      Research that investigates cancers that occur in adolescents (age range 10-19 years).

Interested in applying? Email Uli and Brittany to let them know.

up to $1.5 million over three years

internal deadline 13/1/21

Minimum data

20 January 2021

MRFF 

Efficient Use of Existing Medicines

GO4450 on GrantConnect: https://www.grants.gov.au/     

More information can be found here.

Preventive and Public Health Research Initiative - 2020 Efficient Use of Existing Medicines Grant Opportunity will support Australian medical research projects that conduct clinical trials to address one of the following topics:

• safer and more efficient ways to use high-cost medicines for one or more specific indications without compromising effectiveness
  • priority areas include biological agents and other high-cost medicines
• other therapeutic indications for existing medicines that are not currently approved by the Therapeutic Goods Administration
  • priority areas include off-patent and other low-cost medicines.

Priority will be given to clinical trials investigating changes in the use of medicines that have the greatest potential impact on patients, clinical care and/or health service delivery.

The anticipated outcome of the research is to improve the health and wellbeing of Australians through clinical trials that investigate the more efficient and effective use of existing medicines. 

Interested in applying? Email Uli and Brittany to let them know.

MRFF 

Maternal Health and First 2000 Days, Early Childhood, and Exercise and Nutrition Grant Opportunity

GO4446 on GrantConnect: https://www.grants.gov.au/

More information can be found here.

Preventive and Public Health Research Initiative supports research that focuses on one or more of the following priorities: maternal health, early childhood, or exercise and nutrition.

The objectives of this grant opportunity are to:

• foster new discoveries that lead to practice changes in community and clinical settings 
• increase collaboration across academic disciplines, policy makers and health services to better understand the social, cognitive and emotional aspects of people’s health choices
• develop guidance, tools and interventions to support Australians to adopt positive behaviour change and to live active and healthy lives, and
• improve health outcomes for Australians living with chronic and complex disease through innovative public health approaches, particularly for Aboriginal and Torres Strait Islander peoples and for, disadvantaged regional and rural and culturally and linguistically diverse communities.

Interested in applying? Email Uli and Brittany to let them know.

on GrantConnect: https://www.grants.gov.au/     

UQ guidelines can be found here.

Non-medical research only - see ARC policy on medical research.

Interested in applying? Email Uli and Brittany to let them know.

$30,000.00 to $2,500,000.00

for projects up to 5 years

Individual Investigator Research Grant Awards are designed to concentrate research inareas that will have the greatest potential to move towards treatments and cures forRYR-1-related diseases

Click here for more information

A.Novel therapeutic approaches to RYR-1-related diseases. ​All approaches will beconsidered, but potential interventions include:a.Gene Editing (e.g., CRISPR/Cas9, Base editing, Prime editing, etc.).b.Gene replacement therapy (viral vectors and non-viral technologies).c.Therapeutic strategies utilizing protein and small-molecule binders.d.Therapeutic strategies utilizing nanotechnology/nanoparticles.e.Development of therapeutic interventions that modify RyR1 receptor activity reduce muscle degradation, and/or increase regenerative capacity of skeletalmuscle.

B.Prevalence of RYR-1-Related Diseasesa.The most commonly cited prevalence of RYR-1-related myopathy is 1:90,000,and is based on a study from 10 years ago. This is considered a marked6underestimate of the true prevalence of this disease.b.An updated prevalence study is needed and would exploit data from thenumerous international patient registries/databases

Interested in applying? Email Uli and Brittany to let them know.

MRFF

Cardiovascular Health Mission

Minimum data and internal close

17 Feb 2021

3 Mar 2021

MRFF

Genomics Health Futures Mission Grant Opportunity

MRFF

Traumatic Brain Injury Mission 

MRFF

Stem Cell Therapies 

GrantConnect: https://www.grants.gov.au/

GO4317

The ICTC will provide support for Australian research teams to conduct clinical trial research in collaboration with international counterparts. Applications to this grant opportunity must propose a single clinical trial that will achieve the following outcomes: promote Australian involvement in international collaborative investigator-initiated clinical trials research through the establishment and co ordination of clinical trial site/s in Australia; and provide high-quality evidence of the effectiveness of novel health treatments, drugs or devices in ‘usual care’ settings, which will support a decision on whether to deliver the intervention in an Australian setting. Novel health treatments include new and innovative applications of existing interventions.

Interested in applying? Email Uli and Brittany to let them know.

MRFF

Dementia, Ageing and Aged Care

2020 Dementia, Ageing and Aged Care Grant Opportunity will support Australian medical research and medical innovation projects that:

• Stream 1 (Targeted Call for Research (TCR)): identify an appropriate suite of measures that enable appraisal of local organisation and system performance to assess the impact of new care delivery models and quality improvement for people living with dementia
• Stream 2 (TCR): develop interventions that deliver holistic and multidisciplinary care after diagnosis to improve quality of life for people living with dementia and their carers, including:
  • using digital technologies to support care
  • managing transitions between care types and settings
  • managing disease progression
• Stream 3 (TCR): develop new and improved diagnostic and prognostic tools for dementia, including biological markers of disease onset and progression
• Stream 4 (TCR): conduct research to understand and address barriers to effective infection control practices in aged care settings and during transitions.

The intended outcomes of the research funded by this grant opportunity is to improve the health and wellbeing of Australians:

• Stream 1 (TCR): living with dementia by supporting assessment and adoption of improved care delivery models 
• Stream 2 (TCR): living with dementia and their carers by developing and supporting adoption of new patient centred care approaches 
• Stream 3 (TCR): living with dementia by enabling earlier and more effective diagnosis and better understanding of disease progression
• Stream 4 (TCR): by reducing the incidence of infectious disease amongst residents in aged care settings and during transitions.

Applicants to this grant opportunity must propose research that addresses one of the four Streams of research. An application may be submitted to one of the above four Streams only. 

Interested in applying? Email Uli and Brittany to let them know.

National Foundation for Medical Research

NFMRI

General round:

Open nationally across all diseases and conditions affecting humans. Applications that fall within portfolios 2 & 3 only. More information about this grant round, including the EOI form, can be found here.

Cystic fibrosis round:

 Cystic Fibrosis applications that fall within portfolios 1, 2 & 3 (preference for 2 & 3), open nationally. More information about this grant round, including forms, once available, can be found here.

general round open

cystic fibrosis round - opens 28 April 21

general round:

18 March 21

cystic fibrosis:

16 June 21

Brain & Behaviour Research Foundation

BBRF

BBRF Young Investigator Grant

The BBRF Young Investigator Grant provides support for the most promising young scientists conducting neurobiological research. Two-year awards up to $70,000, or $35,000 per year are provided to enable promising investigators to either extend research fellowship training or begin careers as independent research faculty. Basic and/or clinical investigators are supported, but research must be relevant to serious brain and behavior disorders such as schizophrenia, mood disorders, anxiety disorders or child and adolescent mental illnesses.

The YI Grant is intended to support advanced post-doctoral fellows, instructors and assistant professors (or equivalent).

For more information see website.

up to 2 years;

up to US$70 total

HFSP Research Grants support innovative basic research into fundamental biological problems with emphasis placed on novel and interdisciplinary approaches that involve scientific exchanges across national and disciplinary boundaries (see guidelines).

Participation of scientists from disciplines outside the traditional life sciences such as biophysics, chemistry, computational biology, computer science, engineering, mathematics, nanoscience or physics is recommended because such collaborations have opened up new approaches for understanding the complex structures and regulatory networks that characterize living organisms, their evolution and interactions.

Research grants are provided for teams of scientists from different countries who wish to combine their expertise in innovative approaches to questions that could not be answered by individual laboratories. Preliminary results are not required and applicants are expected to develop new lines of research through the research collaboration.

It is understood that such research inherently contains risks and HFSP expects that teams of applicants address the risks and outline mitigation strategies for their research in case of failure and how they intend to achieve their goals.

Applications for applied research, including medical research typically funded by national medical research bodies, will be deemed ineligible (see guidelines).

Team members should not have collaborated before, they will normally not have published original research together, and the project must be significantly different from their ongoing research.

Two types of Grant are available: Research Grants – Early Career and Research Grants – Program.

The amount paid depends on the number of team members which normally should be 2 - 4.

Two members from the same country are acceptable if the team can convince the reviewers that both members are essential. 

No detailed budget is required

LoI Submission by 30 March 2021

Full applications are invited to be submitted by mid September

Fight MND

IMPACT Grants

IMPACT (IMProving and ACcelerating Translation) Grants support projects focused on one or more of the following key issues contributing to the lack of translation of effective treatments through to clinical trial for MND/ALS:

1. Disease heterogeneity
2. Lack of relevant preclinical models
3. A lack of reliable disease biomarkers
4. The challenge of drug delivery into the brain
5. A lack of effective targeted gene therapies
6. The untapped potential of stem cell therapy

Click here to download a copy of the IMPACT Grant Criteria

Click here to download the IMPACT Grants Coversheet

Tomorrow Fund

https://www.ampstomorrowfund.com.au/

Every year, AMP’s Tomorrow Fund offers $1 million in grants to amazing Australians doing great things.

Individuals of all ages, walks of life and interests – including scientists, social entrepreneurs, educators, artists, athletes, musicians and more – can apply for grants.

Interested in applying? Email Uli and Brittany to let them know.

April 2021

TBA

NHMRC

Ideas grants

The expected outcomes are:

• innovative and creative research
• funding of researchers at all career stages, and
• funding any area of health and medical research from discovery to implementation.

The scheme will provide particular opportunities for early and mid-career researchers. It is expected that the CIA will have the scientific leadership and skills to achieve the proposed project aims

Interested in applying? Email Uli and Brittany to let them know.

Cancer council

CCQ accelerating collaborative Research Grants

Cancer Council Queensland has implemented a new scheme for cancer research funding called the Accelerating Collaborative Cancer Research (ACCR) grants scheme. The ACCR grants scheme has replaced CCQ’s long-running Cancer Research Project Grants scheme.

The new funding scheme is intended to:

• Stimulate innovative, collaborative cancer research.
• Develop the capacity of high-quality cancer research groups in Queensland.
• Accelerate the progress of research to improve the survival and well-being of cancer patients.

Up to two ACCR grants will be awarded in 2020 for funding to commence on 1 January 2021. Each grant will:

• Be for a maximum term of four years.
• Provide a total of $500,000 per annum, comprising $350,000 per annum from CCQ and a required cash co-contribution of $150,000 per annum from the administering institution.

May

no date yet for 2021

Various opportunities open throughout the year. Check here for current opportunities: https://cdmrp.army.mil/funding/prgdefault

Some selected funding opportunities from that website are :

Breast Cancer Research Program 

Breakthrough award Levels 1 and 2: https://cdmrp.army.mil/funding/pa/FY20-BCRP-BTA12-2.pdf

• Funding Level 1: Innovative, high-risk/high-reward research that is in the earliest stages of idea development or is an untested theory that addresses an important problem. To foster research that yields new avenues of investigation, preliminary data are not required. Proof of concept is the anticipated outcome.
• Funding Level 2: Preclinical research that is already supported by substantial preliminary or published data and strongly validates clinical translation in a well-defined context within the breast cancer landscape.

Era of Hope Scholar Award: https://cdmrp.army.mil/funding/pa/FY20-BCRP-EOHS-2.pdf

The Era of Hope Scholar Award supports individuals early in their careers who have demonstrated significant potential to effect meaningful change in breast cancer. These individuals should be exceptionally talented scientists who have shown that they are the “best and brightest” in their field(s) through extraordinary creativity, vision, innovation, and productivity. They should have demonstrated experience in forming effective partnerships and collaborations and must exhibit strong potential for future leadership in breast cancer research. As the intent of the Era of Hope Scholar Award is to recognize creative and innovative individuals rather than projects, the central features of the award are the demonstrated ability of the individual named as the Principal Investigator (PI) in the application to go beyond conventional thinking in their field and the innovative contribution that the PI can make toward ending breast cancer. The application should articulate a vision that challenges current dogma and demonstrates an ability to look beyond tradition and convention

Interested in applying? Email Uli and Brittany to let them know.

Breakthrough:

Level 1:

US$450k - 750k

Level 2:

US$1.5-2M

Era of Hope:

up to US$3M total

LoI: 

11 March 2021

full application if invited: March 25  - June 23 2021 depending on level

Duchenne Muscular Dystrophy Research Program

Idea Development Award: https://cdmrp.army.mil/funding/pa/FY20-DMDRP-IDA.pdf

All applications for the FY20 DMDRP Idea Development Award (IDA) must address opportunities and challenges in the development of safe and effective macromolecular and cellular therapies that address primary pathology of DMD. Eligible therapeutic strategies include: gene therapy, genome editing, oligonucleotide therapies, exon skipping, protein therapeutics, and cell therapies. Therapies that will be efficacious across the life-span, particularly in adolescents and adults are encouraged

Interested in applying? Email Uli and Brittany to let them know.

Neurotoxin Exposure Treatment Parkinson's Research Program

The vision of the NETP Program is to eliminate Parkinson’s disease through neurotoxin exposure and treatment-related research in partnership with scientists and consumers.The NETP Program invests in scientific research to better understand and treat the neuro-degenerative effects of PD associated with military deployment and environmental and/or occupational exposures. Research into military service-related risk factors is critical for past, present, and future Service members who may be affected by PD. Focus areas include:

• Quantifiable gene - environment interactions and the risk for or progression of Parkinson’s disease following neurotoxin exposure.

• Basic biology of non-motor symptoms that could lead to the development of new treatments for Parkinson’s disease following neurotoxin exposure.

• System-level mechanism of dopamine refractory motor symptoms in Parkinson’s disease, including postural instability, freezing of gait, and treatment-associated dystonia, that could lead to development of new treatments in patients with neurotoxin exposure

A summary of award mechanisms (ECR / professor level) can be found here: https://cdmrp.army.mil/funding/pdf/20netpreftable.pdf

Interested in applying? Email Uli and Brittany to let them know.

Parkinsons

ECR (<10 years post PhD):

up to US$400k for up to 2 years

Innovator grants

MND researchers working in Australia in applied research or fields relevant to the cause, treatment or cure of MND. Applicants must be Australian citizens or have permanent resident status.

The Betty and John Laidlaw MND Research Prize

The Betty and John Laidlaw MND Research Prize aims to reward an outstanding *mid-career researcher with a demonstrated background of excellence in neuroscience research.

The Prize is for an innovative 2-year project to advance the understanding of **classical MND with a clear potential for effective treatments. It aims to support research commencing in the calendar year 2021.

For more info about both see: https://www.mndaust.asn.au/Discover-our-research/grants-and-research-meetings/Apply-for-a-grant.aspx

Interested in applying? Email Uli and Brittany to let them know.

Innovator:

Up to $100k

One year

Betty and John Laidlaw MND Research Prize

mid-career researchers: 5-12 years post PhD

up to $200 for up to 2 years

August

Project grants

https://www.dementia.org.au/research/grants

The Dementia Australia Research Foundation Project Grants are open to Australian-based dementia researchers undertaking projects across all forms of dementia and in any topic area; biomedical (lab-based), clinical, psychosocial, or knowledge translation research projects will be considered.

World Class Research Projects

The Dementia Centre for Research Collaboration (DCRC) is pleased to announce the following grant round to fund World Class Research Projects including trials and studies to produce evidence, evaluate interventions, promote practice change or inform policy

https://www.dementia.org.au/sites/default/files/2020-07/2020_DCRC_WCR_GRANTS_InformationForApplicants.pdf

Interested in applying? Email Uli and Brittany to let them know.

up to $75k pa

Early and mid- career researchers (i.e. level A, B and C only)

max $600k per grant

MTPConnect is a not-for-profit organisation which aims to accelerate the rate of growth of the medical technologies, biotechnologies and pharmaceuticals sector to achieve greater commercialisation and establish Australia as an Asia-Pacific hub for MTP companies. It was formed in November 2015 as part of the Federal Government’s Industry Growth Centres Initiative. They operate several initiatives:

The Biomedical Translation Bridge program aims to nurture early stage health and medical research ventures to reach proof-of-concept stage with potential to attract further capital and support. EOIs need to clearly articulate clinical benefit to patients and an advantageous point of differentiation from anything similar on the market or in development.

The Biomedical Translation Bridge program is an initiative of the Medical Research Future Fund, providing up to $1 million in matching funding to nurture the translation of new therapies, technologies and medical devices through to the proof of concept stage.

The Australian Government's $45 million BioMedTech Horizons is an initiative to support innovative collaborative health technologies, drive discoveries towards proof-of-concept and commercialisation that address key health challenges as well as maximise entrepreneurship and idea potential.   Investments from the program will be focused on supporting cutting-edge ideas towards proof-of-concept and commercialisation. Head to the BioMedTech Horizons page for more details.

MTPConnect is charged with driving innovation and growth in the medical technology, biotechnology and pharmaceutical sector. With the sector on the cusp of realising it’s full commercial potential, MTPConnect is kickstarting collaborative, industry-led projects through a dollar-for-dollar matched Project Fund Program.

We are looking for consortia large and small to creatively address some of the barriers to growth, as outlined in our 10-year Sector Competitiveness Plan, to share in a funding pool of $15.6 million. Head to the Project Fund Program page for more details.

Interested in applying? Email Uli and Brittany to let them know.

normally various times throughout the year

currently - no information about new rounds available

NIH

NIH have their own search engine for grant opportunities:

https://grants.nih.gov/funding/searchguide/index.html#/

Examples are:

Notice of Special Interest: Selective Cell and Network Vulnerability in Aging and Alzheimer’s Disease

Areas of research interest and opportunity include, but are not limited to, the following:

• Identification of neural cell populations, brain regions, neural circuits, and/or large-scale networks (connectomes) that contribute to vulnerability in brain aging and AD.

• Comprehensive single-cell transcriptomics (e.g. RNAseq), epigenetics (e.g. chromatin remodeling, DNA methylation), and/or genomics (e.g. sequencing for somatic mutations) of neurons and glial cells in different brain regions at different ages and pathological stages of AD.

• Multidisciplinary and multiplexed technological approaches to single-cell 'omics,' electrophysiology, and connectivity for comprehensive and integrative studies of selective vulnerability to neuro- and glial-degeneration in aging and AD.

• Mechanisms underlying selective cell sensitivity to beta-amyloid, tau, and other proteinopathies, including cell-to-cell spread of pathogenic proteins and the role of proteostasis network function in selective cell and circuitry vulnerability.

• Role of cell-intrinsic versus cell non-autonomous and/or environmental factors in selective vulnerability or adaptive responses to cell or network stressors or neurodegenerative events.

• Role of differential activity and connectivity properties of neuronal populations, circuits, and networks in vulnerability (or resiliency) to aging and AD.

• Characterization of the molecular, cellular, synaptic, and neural circuitry mechanisms underlying brain plasticity and resilience in counteracting vulnerability to neurodegeneration in aging and AD.

For more information please see: https://grants.nih.gov/grants/guide/notice-files/NOT-AG-19-033.html

Notice of Special Interest: Promoting Fundamental and Applied Research in Inflammation Resolution (NOT-ES-20-018):

This Trans-NIH partnership seeks to support research to gain comprehensive understanding of the biology of the resolution of inflammation to elucidate the critical distinctions between resolution and anti-inflammatory mechanisms.

For more information please see: https://grants.nih.gov/grants/guide/notice-files/NOT-ES-20-018.html

Notice of Special Interest (NOSI): Sleep and Substance Use Disorders (NOT-DA-20-021)

The purpose of this noticeis to inform potential applicants to the National Institute on Drug Abuse (NIDA) about a special interest in research project applications focusing on the relationship between processes that regulate sleep/circadian rhythm and the risk, trajectory and treatment of substance use disorders. Identifying sleep/circadian mechanisms and determining the directionality of sleep and substance use disorder interactions addresses a knowledge gap and can present new opportunities for improved therapy and outcomes. Multi-disciplinary, multiple-investigator teams of researchers combining expertise in substance use disorders and mechanisms of sleep/circadian rhythms would be optimal in addressing these questions.

For more information please see: https://grants.nih.gov/grants/guide/notice-files/NOT-DA-20-021.html

Notice of Special Interest: Alcohol and Cancer Control: NOT-CA-20-034

​This Notice highlights interest in receiving investigator-initiated grant applications addressing the effects of alcohol on human health across the cancer control continuum.

For more information see: https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-034.html

Notice of Special Interest (NOSI): Use of Biological Information to Understand How the Interplay of Environmental Exposures and Genes Influences Cancer Risk: NOT-CA-20-002

​The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants to the National Cancer Institute (NCI) of special interest to promote research that incorporates biological information within population-based cancer epidemiologic studies to identify and understand how the interplay between environmental exposures (e.g., chemical and physical exposures, dietary, and other exposures) and germline genetic variation contribute to cancer risk. Biological information can include functional annotations of the genome (e.g., methylation, promoters or enhancers); methods of linking variants to genes (e.g., expression quantitative trait loci analysis), gene pathway or network-based approaches (e.g., network modeling); analysis of metabolites or biomarkers, or data from mechanistic studies.

For more information see: https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-002.html

Notice of Special Interest: Mechanisms Underlying the Contribution of Sleep Disturbances to Pain NOT-HD-19-020

Successful pain management (and prevention) necessitate a better understanding of how sleep disturbances (and their associated biological mechanisms) contribute to chronic pain, including its transition from acute pain. It is likely that chronic pain prevention and treatment can be more effective with explicit integration of sleep (and mental health).

For more information see: https://grants.nih.gov/grants/guide/notice-files/NOT-HD-19-020.html

Early-Stage T1 Translational Aging Research (Bench to Bedside) for the Development of Novel Therapeutics (R21/R33 Clinical Trial Optional) PAR-19-305

This Funding Opportunity Announcement (FOA) encourages Exploratory/Developmental Phased Innovation (R21/R33) grant applications to facilitate early-stage T1 translation (bench-to-bedside) of discoveries from basic and applied research in aging into novel therapeutics for the prevention and treatment of clinical conditions related to aging and/or multiple chronic conditions in older people (e.g., sarcopenia, heart failure with preserved ejection fraction (HFpEF), immunosenescence, metabolic syndrome, chronic kidney disease). This includes the development of pharmacological strategies such as new classes of compounds (e.g., senolytics, anti-inflammatory agents, modulators of proteostasis and autophagy), natural products (or their derivatives, mimics, and synthetic equivalents), biologics, stem/progenitor cell-based therapies, and the repurposing of Food and Drug Administration (FDA)-approved drugs.

For more information see: https://grants.nih.gov/grants/guide/pa-files/PAR-19-305.html

Interested in applying? Email Uli and Brittany to let them know.

R01: NIH Research Project Grant Program supports specific research projects over 3-5 years. There  is no funding limit. 

R03: NIH small grant program - 2 years of funding up to USD $50k per year 

R21: Exploratory / Developmental Research Grant Award supports early stages of project development and novel ideas that come with risk. Funding is limited to two years and USD $275k

Commencing in August, McAllister & Quinn (M&Q) will deliver two 1-hour training webinars providing an overview of the NIH and how to craft a competitive NIH proposal.  Researchers interested in receiving tailored feedback and one-on-one coaching from M&Q can then submit a draft concept paper to UQ R&I, with up to eight UQ researchers selected to participate in the full training program, working with M&Q and the Office of Sponsored Research (OSR) to develop an NIH solicitation response.  The expected minimum time commitment for the complete training program is 8-15 hours over 14 weeks. 

Health sciences researchers interested in submitting a proposal for NIH funding in 2020/2021 are invited to submit an NOI to RSVP for this training program.  NOIs close with the UQ R&I International Grants team (internationalgrants@research.uq.edu.au) on Tuesday 18 August 2020

Training program:

Webinar #1: Introduction to U.S. Federal Research Funding in the Health and Biomedical Sciences – 19 August 2020, 9:30 – 10:30am

Webinar #2: Best Practices for Crafting a Competitive Submission to the National Institutes of Health – 9 September, 9:30 – 10:30am

Following the first Webinar, interested researchers are invited to complete a draft concept paper for consideration by OSR and M&Q.  Up to eight UQ researchers will then be selected to participate in the full training program. 

• Draft Specific Aims page (NIH Concept paper) due to UQ R&I – 2 September 2020, 5pm
• M&Q introductory call for training cohort – anticipated 14-16 September 2020 (TBC)
• Feedback and coaching from M&Q – September to November 2020

standard due dates are:

R01 - 5 February, 5 June, 5 October

R03 - 16 February, 16 June, 16 October

R21 - 16 February, 16 June, 16 October

NOT-ES-20-018:

open October 2020 through to May 31, 2024

NOT-DA-20-021:

open until 8/9/2023

NOT-CA-20-034:

open now until 9/9/23

NOT-CA-20-002:

open until 8/1/22

NOT-HD-19-020:

open until 8/9/22

PAR-19-305​:

open until 17/7/22

MDA is committed to transforming the lives of people affected by muscular dystrophy, ALS and related neuromuscular diseases. We do this through innovations in science and innovations in care. As the largest source of funding for neuromuscular disease research outside of the federal government, MDA has committed more than $1 billion since our inception to accelerate the discovery of therapies and cures. Research we have supported is directly linked to life-changing therapies across multiple neuromuscular diseases. In addition to the work MDA does to provide the best clinical care and support to families living with neuromuscular disease, funding the most promising and innovative research is a top priority.

DA provides support for research throughout the pipeline of drug development from discovery research through clinical trials. Funding opportunities exist for both academic investigators as well as for biotech and pharma seeking to develop therapies for neuromuscular disease.

MDA offer a variety of funding opportunities:

Discovery research: Research grants and Development grants

Tranlsational Research: MDA Venture Philanthropy Program

Clinical Research: Clinical Research Grants and Clinical Research Network Grants

For more information see: https://www.mda.org/science/funding-opportunities

Research grants:

$100k pa for up to 3 years

Tranlsational grants:

2-3 years

R&D up to US$300k

Preclinical (up to US$500k)

Early clinical (Phase 1/2: up to US$1M)

Clinical Research

up to 3 years, up to US$500k and US$1M for network grants

Ovarian Cancer Research grants:

Pilot study

Pilot Study Program awards will support investigator-initiated projects in all areas of ovarian cancer research. In addition, projects designed to analyze data from already funded clinical trials will be considered.

For more info see: https://rivkin.org/wp-content/uploads/2019/12/Rivkin-Pilot-Study-Award-Guidelines-rev-08-19-for-2020.pdf

1 year

US$75k

https://www.brightfocus.org/grants/types-grants

Alzheimer's DIseases Research Program:

BrightFocus provides research funds for U.S. domestic as well as international researchers pursuing pioneering research leading to greater understanding, prevention, and treatment of Alzheimer's disease.

The goal of the program is to accelerate our understanding of the biological mechanisms underlying Alzheimer’s Disease and related dementias as well as innovative approaches to better diagnose, prevent or delay the progress of the disease. Preference is made for exciting pilot projects that would not, at their present stage, be competitive for large government or industry awards. Typically, these awards are made to early stage investigators, or to more established investigators who are proposing particularly innovative research.

Interested in applying? Email Uli and Brittany to let them know.